Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose
Objective: To evaluate the short-term effect of glycaemic control and intravitreal ranibizumab treatment on diabetic macular edema (DME) and to assess the correlation between HbA1c and certain serum cytokines. Design: A prospective study of 43 participants with HbA1c levels exceeding 53 mmol/mol (7%...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Selcuk University Press
2022-12-01
|
| Series: | Genel Tıp Dergisi |
| Subjects: | |
| Online Access: | https://dergipark.org.tr/tr/download/article-file/2716782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841563624054718464 |
|---|---|
| author | Hürkan Kerimoğlu İbrahim Kılınc Bülent Savut Mustafa Kulaksızoğlu Günhal Şatırtav Gülfidan Bitirgen Emine Tınkır Kayıtmazbatır |
| author_facet | Hürkan Kerimoğlu İbrahim Kılınc Bülent Savut Mustafa Kulaksızoğlu Günhal Şatırtav Gülfidan Bitirgen Emine Tınkır Kayıtmazbatır |
| author_sort | Hürkan Kerimoğlu |
| collection | DOAJ |
| description | Objective: To evaluate the short-term effect of glycaemic control and intravitreal ranibizumab treatment on diabetic macular edema (DME) and to assess the correlation between HbA1c and certain serum cytokines.
Design: A prospective study of 43 participants with HbA1c levels exceeding 53 mmol/mol (7%) and with DME, as detected by spectral domain optical coherence tomography (SDOCT).
Subjects: Participants were grouped according to their initial best corrected distance visual acuity (BCVA). Group 1 was treated with three monthly doses of intravitreal ranibizumab (0.5 mg) injections, and Group 2 was followed without treatment.
Methods: Serum cytokine levels, including interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1(MCP-1), and vascular endothelial growth factor (VEGF) were analysed at the beginning and at the end of 3 months, using enzyme-linked immunosorbent assays (ELISA).
Results: A significant decrease in macular thicknesses (except for one quadrant) was observed in Group. Changes in serum cytokine levels were not correlated with HbA1c decrease. Serum VEGF level was significantly increased in Group 1, despite the intravitreal treatment.
Conclusion: Short-term glycaemic control alone had limited value in the treatment of DME. The therapeutic effect of intravitreal treatment on DME supports the role of the local cytokine milieu in the pathophysiology. |
| format | Article |
| id | doaj-art-7847670a72e14779835b43c260a67d9d |
| institution | Kabale University |
| issn | 2602-3741 |
| language | English |
| publishDate | 2022-12-01 |
| publisher | Selcuk University Press |
| record_format | Article |
| series | Genel Tıp Dergisi |
| spelling | doaj-art-7847670a72e14779835b43c260a67d9d2025-01-02T23:43:04ZengSelcuk University PressGenel Tıp Dergisi2602-37412022-12-0132677478010.54005/geneltip.1191169154Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucoseHürkan Kerimoğlu0İbrahim Kılınc1Bülent Savut2Mustafa Kulaksızoğlu3Günhal Şatırtav4Gülfidan Bitirgen5Emine Tınkır Kayıtmazbatır6Department of Ophthalmology, Meram Faculty of Medicine, Necmettin Erbakan UniversityDepartment of Medical Biochemistry, Meram Faculty of Medicine, Necmettin Erbakan UniversityDepartment of Endocrinology and Metabolic Diseases, Necip Fazil State HospitalDepartment of Endocrinology and Metabolic Diseases, Meram Faculty of Medicine, Necmettin Erbakan UniversityDepartment of Ophthalmology, Meram Faculty of Medicine, Necmettin Erbakan UniversityDepartment of Ophthalmology, Meram Faculty of Medicine, Necmettin Erbakan UniversityDepartment of Ophthalmology, Sorgun State HospitalObjective: To evaluate the short-term effect of glycaemic control and intravitreal ranibizumab treatment on diabetic macular edema (DME) and to assess the correlation between HbA1c and certain serum cytokines. Design: A prospective study of 43 participants with HbA1c levels exceeding 53 mmol/mol (7%) and with DME, as detected by spectral domain optical coherence tomography (SDOCT). Subjects: Participants were grouped according to their initial best corrected distance visual acuity (BCVA). Group 1 was treated with three monthly doses of intravitreal ranibizumab (0.5 mg) injections, and Group 2 was followed without treatment. Methods: Serum cytokine levels, including interleukin (IL)-1β, IL-6, IL-8, tumor necrosis factor-alpha (TNF-α), monocyte chemoattractant protein-1(MCP-1), and vascular endothelial growth factor (VEGF) were analysed at the beginning and at the end of 3 months, using enzyme-linked immunosorbent assays (ELISA). Results: A significant decrease in macular thicknesses (except for one quadrant) was observed in Group. Changes in serum cytokine levels were not correlated with HbA1c decrease. Serum VEGF level was significantly increased in Group 1, despite the intravitreal treatment. Conclusion: Short-term glycaemic control alone had limited value in the treatment of DME. The therapeutic effect of intravitreal treatment on DME supports the role of the local cytokine milieu in the pathophysiology.https://dergipark.org.tr/tr/download/article-file/2716782diabetes mellitus, type 2glycaemic controlglycated haemoglobin a1cmacular edemaserum cytokinesvascular endothelial growth factordiyabetes mellitus, tip 2glisemik kontrolglikolize hemoglobin a1cmaküler ödemserum sitokinlerivasküler endotelyal büyüme faktörü |
| spellingShingle | Hürkan Kerimoğlu İbrahim Kılınc Bülent Savut Mustafa Kulaksızoğlu Günhal Şatırtav Gülfidan Bitirgen Emine Tınkır Kayıtmazbatır Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose Genel Tıp Dergisi diabetes mellitus, type 2 glycaemic control glycated haemoglobin a1c macular edema serum cytokines vascular endothelial growth factor diyabetes mellitus, tip 2 glisemik kontrol glikolize hemoglobin a1c maküler ödem serum sitokinleri vasküler endotelyal büyüme faktörü |
| title | Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| title_full | Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| title_fullStr | Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| title_full_unstemmed | Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| title_short | Short-term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| title_sort | short term impact of glycaemic control and intravitreal ranibizumab treatment on serum cytokine levels and diabetic macular edema in patients with unregulated blood glucose |
| topic | diabetes mellitus, type 2 glycaemic control glycated haemoglobin a1c macular edema serum cytokines vascular endothelial growth factor diyabetes mellitus, tip 2 glisemik kontrol glikolize hemoglobin a1c maküler ödem serum sitokinleri vasküler endotelyal büyüme faktörü |
| url | https://dergipark.org.tr/tr/download/article-file/2716782 |
| work_keys_str_mv | AT hurkankerimoglu shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT ibrahimkılınc shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT bulentsavut shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT mustafakulaksızoglu shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT gunhalsatırtav shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT gulfidanbitirgen shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose AT eminetınkırkayıtmazbatır shorttermimpactofglycaemiccontrolandintravitrealranibizumabtreatmentonserumcytokinelevelsanddiabeticmacularedemainpatientswithunregulatedbloodglucose |